5 completed, 4 recruiting, 1 not yet recruiting, 1 terminated. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 5, Recruiting 4, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 4 | Recruiting 3, Terminated 1 |
Follow Intestinal Polyposis: new trials by email Literature Review of Intestinal Polyposis trials Research Report on Intestinal Polyposis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). ST316 IV - Familial Adenomatous Polyposis (FAP) | Phase 1 | Not yet recruiting | Sapience Therapeutics | 40 | 2027-01-04 | 2026-08-12 |
| Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Tegavivint - Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | HonorHealth Research Institute | 126 | 2026-02-17 | 2026-03-11 |
| Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 Biopsy Procedure, Biospecimen Collection, Colonoscopy - Colorectal Adenomatous Polyp, Colorectal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2025-10-06 | 2026-10-15 |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) REC-4881, Placebo - Familial Adenomatous Polyposis | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 67 | 2023-07-10 | 2026-06-05 |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
| A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis JNJ-64251330 - Adenomatous Polyposis Coli | Phase 1 | Completed | Janssen Research & Development, LLC | 42 | 2021-11-10 | 2023-06-02 |
| A Study of Guselkumab in Participants With Familial Adenomatous Polyposis Guselkumab, Placebo - Adenomatous Polyposis Coli | Phase 1 | Completed | Janssen Research & Development, LLC | 77 | 2018-11-19 | 2025-02-03 |
| Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Bevacizumab-IRDye800CW, Near infrared fluorescence endoscopy platform - Adenomatous Polyposis Coli | Phase 1 | Completed | University Medical Center Groningen | 17 | 2014-03-01 | 2023-10-27 |
| Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma Synthetic Human Secretin - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 4 | 2006-11-01 | 2013-06-24 |
| Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP) Black raspberry (BRB) Slurry, Black Raspberry (BRB) Suppositories, Black Raspberry (BRB) Placebo Slurry - Familial Adenomatous Polyposis | Phase 1 | Completed | The Cleveland Clinic | 34 | 2005-12-01 | 2016-02-15 |
| Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis celecoxib, placebo - Colorectal Cancer, Precancerous Condition | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2002-11-21 | 2018-11-07 |
Adenomatous Polyposis Coli (10) · Colorectal Neoplasms (4) · Desmoid Tumors (2) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Craniopharyngioma (1) · Diabetes Mellitus (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Peutz-Jeghers Syndrome (1) · Polyps (1) · Precancerous Conditions (1) · Prostatic Neoplasms (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Digestive System Diseases (11) · Digestive System Neoplasms (11) · Gastrointestinal Diseases (11) · Genetic Diseases, Inborn (11) · Intestinal Diseases (11) · Neoplasms by Site (11) · Neoplastic Syndromes, Hereditary (11) · Adenoma (10) · Adenomatous Polyps (10) · Colonic Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Neoplasms (10) · Neoplasms (10)
Bevacizumab (1) · Biopsy (1) · Celecoxib (1) · Colonoscopy (1) · Endoscopy (1) · Fluorouracil (1) · Leucovorin (1) · Nivolumab (1) · Oxaliplatin (1) · Secretin (1) · Sigmoidoscopy (1) · Specimen Handling (1) · Suppositories (1) · guselkumab (1) · trifluridine tipiracil drug combination (1)
Janssen Research & Development, LLC (2) · HonorHealth Research Institute (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Parabilis Medicines, Inc. (1) · Recursion Pharmaceuticals Inc. (1) · Sapience Therapeutics (1) · The Cleveland Clinic (1) · University Medical Center Groningen (1)
United States (9) · Netherlands (3) · France (2) · Germany (2) · Puerto Rico (2) · Spain (2) · Australia (1) · Israel (1) · Poland (1) · South Korea (1) · Sweden (1)
Alexander G Raufi, MD (1) · Benjamin Oshrine (1) · Carol A Burke, MD (1) · Jan H Kleibeuker, MD, senior full professor (1) · Jan Jakob Koornstra, MD PhD (1) · Naoki Takahashi, M.D. (1) · Patrick M. Lynch, MD, JD (1) · Wouter B Nagengast, PharmD MD PhD (1)
PMID 20234350, PMID 37119510, PMID 39956770
2019 (1), P30CA046592 (1), UG1CA242632 (1)